CIAS
VKTX icon

Capital Investment Advisory Services’s Viking Therapeutics VKTX Stock Holding History

Capital Investment Advisory Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,850
Closed -$26K – 1236
2019
Q3 		$26K Hold
3,850
– – 0.01% 739
2019
Q2 		$32K Buy
3,850
+2,150
+126% +$18.4K 0.01% 660
2019
Q1 		$17K Buy
1,700
+800
+89% +$6.7K 0.01% 727
2018
Q4 		$7K Buy
+900
New +$10.8K ﹤0.01% 885

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Capital Investment Advisory Services's VKTX Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Viking Therapeutics (VKTX) in Q4 2019, closing a stake of 3,850 shares — an estimated $26K sold.

Capital Investment Advisory Services first reported a position in VKTX in Q4 2018 and held it in 4 quarters. The position peaked at $32K in Q2 2019. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Viking Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 3,850 Viking Therapeutics shares in Q4 2019, an estimated $26K.
  • Capital Investment Advisory Services first reported a position in Viking Therapeutics in Q4 2018 and held it in 4 quarters.
  • Capital Investment Advisory Services's Viking Therapeutics position peaked at $32K in Q2 2019.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.